B · Normal
[Hong Kong stocks’ pharmaceutical sector strengthened, WuXi shares rose 9%] On November 4th, Hong Kong stocks’ pharmaceutical sector strengthened, with innovative drugs and CXO leaders collectively rising. As of press time, WuXi Biologics (02269.HK) and WuXi AppTec (02359.HK) have risen by 9%, BeiGene (06160.HK) has risen by about 8%, and Kangfang Biologics (09926.HK) has risen by about 6%. According to the news, WuXi AppTec, the “biggest CXO”, achieved revenue of 45.54 billion yuan in the first three quarters, a year-on-year increase of 38.6%. Orders on hand were 76.74 billion yuan, with a net increase of approximately 17 billion yuan in the three quarters.
Comments